CQN-CA-BELKIN
25.5.2023 21:47:28 CEST | Business Wire | Press release
The sentence just beneath the bullets should read "The BoostCharge Pro Fast Wireless Charger for Apple Watch + Power Bank 10K is now available for $99.99 USD on Belkin.com, and coming soon to select retailers worldwide." (instead of "The BoostCharge Pro Fast Wireless Charger for Apple Watch + Power Bank 10K is now available for $99.99 USD on Belkin.com.")
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516006027/en/
Belkin BoostCharge™ Fast Wireless Charger for Apple Watch + Power Bank 10K (Photo: Business Wire)
The updated release reads:
BELKIN INTRODUCES THE ULTIMATE POWER BANK – THE BOOSTCHARGE™ FAST WIRELESS CHARGER FOR APPLE WATCH + POWER BANK 10K
Featuring fast charging for Apple Watch and 20W USB-C PD for charging iPhone anytime, anywhere
Belkin, a leading consumer electronics brand for 40 years, today announces a first-of-its-kind power bank providing fast charge capabilities for newer Apple Watch models1 and iPhone simultaneously, on-the-go. Able to fully charge the Apple Watch Series 8 and Apple Watch Series 7 from 0% to 80% in about 45 minutes, and Apple Watch Ultra 0% to 80% in about an hour,2 the BoostCharge Pro Fast Wireless Charger is the perfect solution for portable power in a pinch.
The powerful new charger was designed in California by Belkin’s award-winning design team and intricately engineered to fit most Apple Watch band sizes and styles. It leverages the latest in technology to charge the Apple Watch Series 8 fourteen times, or iPhone 14 twice3.
Product features:
- Supports fast charging for Apple Watch Series 8 and Apple Watch Series 7 from 0% to 80% in about 45 minutes, and Apple Watch Ultra 0% to 80% in about an hour2
- Built with a 20W USB-C PD port for fast charging the power bank itself as well as an additional device
- Provides up to 36 hours of video playback for iPhone 144 with 10,000mAh cell capacity
- Built with overcharge protection and fully certified by USB-IF and MFi to deliver safe, fast, efficient power
- Supports wireless charging for AirPods Pro (2nd generation)
- Includes 12-inch USB-C cable for charging power bank
- Ships in plastic-free retail packaging
- Connected Equipment Warranty covers up to $2500 for peace of mind
The BoostCharge Pro Fast Wireless Charger for Apple Watch + Power Bank 10K is now available for $99.99 USD on Belkin.com, and coming soon to select retailers worldwide.
Media kit is available for download HERE.
About Belkin
Belkin is an accessories market leader delivering power, protection, productivity, connectivity, audio, security, and home automation solutions for a broad range of consumer electronics and enterprise environments. Designed in Southern California and sold in more than 100 countries around the world, Belkin has been a market leader and innovator for 40 years. Its dedication to people-inspired design and quality informs everything from user testing and prototyping process to regulatory compliance, manufacturing and warranty programs. In 2018 Belkin International merged with Foxconn Interconnect Technology to broaden its global influence while maintaining its steadfast focus on R&D, community, education and sustainability.
____________________________
1 Fast charging is only compatible with Apple Watch Series 7, Apple Watch Series 8, and Apple Watch Ultra. Other models will have regular charge times.
2 Testing conducted by Belkin in October 2022; devices tested with latest watchOS 9.0.1 software. Actual results will vary depending on varying factors, including device age, model and usage environment, for individual users.
3 Data based on internal lab testing. Actual results will vary depending on varying factors for individual users.
4 Maximum additional video playback hours calculated by comparing the cell capacity of this power bank with the maximum video playback hours achievable by the iPhone 14 under normal conditions. Actual results will vary depending on varying factors for individual users.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516006027/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom